Stock Price
136.77
Daily Change
0.57%
Yearly
-41.64%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,004.00 -27.00 -0.89% -21.75%
Astellas Pharma 1,763.50 -16.00 -0.90% 17.41%
Eisai 6,830.00 -43.00 -0.63% -12.26%
Agios Pharmaceuticals 35.62 0.11 0.31% -23.46%
Alnylam Pharmaceuticals 183.80 3.06 1.69% 38.96%
Amgen 198.88 -4.59 -2.26% -11.64%
AstraZeneca 8,323.00 47.00 0.57% 4.86%
Bayer 44.67 0.15 0.33% -6.61%
BioCryst Pharmaceuticals 12.06 -0.39 -3.13% 147.64%
Bluebird Bio 10.11 -0.22 -2.13% -77.96%
Bristol-Myers Squibb 53.63 -1.01 -1.85% -14.07%
Exelixis 16.79 -0.12 -0.71% -12.37%
Gilead Sciences 68.93 -1.72 -2.43% 12.78%
GlaxoSmithKline 1,528.00 3.00 0.20% 9.64%
Incyte Corp 67.72 -2.65 -3.77% -20.72%
Ionis Pharmaceuticals 26.50 -0.95 -3.46% -48.16%
J&J 155.93 -3.82 -2.39% 5.75%
Eli Lilly 248.04 -6.79 -2.66% 70.40%
Merck & Co 74.91 0.02 0.03% -8.14%
Moderna Inc 352.43 -16.08 -4.36% 149.93%
Nektar Therapeutics 11.26 0.15 1.35% -31.63%
Novartis 74.00 0.56 0.76% -9.67%
Puma Biotechnology 3.10 0.02 0.65% -74.10%
Pfizer 53.73 1.33 2.54% 36.34%
Ultragenyx Pharmaceutical 75.23 1.52 2.06% -35.91%
Roche Holding 361.40 1.75 0.49% 19.41%
Seattle Genetics 160.00 -5.31 -3.21% -9.81%
Spectrum Pharmaceuticals 1.58 0 0% -65.80%
Sarepta Therapeutics 80.81 0.95 1.19% -44.63%
Acceleron Pharma 178.75 -0.93 -0.52% 57.43%

Indexes Price Day Year
NASDAQ 15538 -245.14 -1.55% 25.76%
US2000 2199 -43.07 -1.92% 19.76%

Mirati Therapeutics
Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.